Formulation Optimization and Assessment of Dexamethasone Orally Disintegrating Tablets Using Box-Behnken Design
Authors
Abstract:
The aim of this study was to prepare orally disintegrating tablets (ODTs) containingdexamethasone (DEX) by direct compression method with sufficient hardness and rapiddisintegration time. In order to save time, money, and human resources in designing andimprovement of formulation, the statistical software Design Expert is used. Box–Behnkenresponse surface methodology was applied to evaluate and optimize the effects of concentrationsof three excipients, Kollidon CL-SF (X1), Pearlitol SD200 (X2), and Prosolv SMCC (X3) asindependent factors on four responses: percentage of drug released after 5 min, disintegratingtime, hardness, and friability. Thirteen formulations offered by the Box–Behnken design wereprepared by direct compression method and ultimate weight of 200 mg, while the amount ofDEX was 4 mg. All formulations were characterized for parameters such as diameter, hardness,weight, thickness, friability, and disintegration time. Following the statistical results, the effectsof independent variables on responses were evaluated and the optimum formulation regardingacceptable responses consisted of 15% Kollidon, 39.66% Pearlitol, and 7.5% Prosolv whichshowed 95.28% release of the drug after 5 min, disintegrating time of 30 sec, 6.1 kg hardness,and 0.12% of friability with an acceptable taste as the optimized formulation.
similar resources
Formulation and Preparation of Orally Disintegrating Tablets Using Innovative Binder
The present study investigates the use of glyceryl palmitostearate (Precirol ATO 5 – coded PATO) as binder in orally disintegrating tablets (ODT), prepared by melt granulation. PATO has been mentioned in literature for its lipophilic nature and fine powder properties, providing excelent coating and slow release of active drugs, but it can also be used for taste masking purposes, with possible a...
full textFormulation design for orally disintegrating tablets containing enteric-coated particles.
The purpose of this study was to investigate the applicability of our newly developed technology (RACTAB® technology) for preparing orally disintegrating tablets (ODTs) containing enteric-coated particles. Tamsulosin hydrochloride (TAM) was used as a model drug contained in the enteric-coated particles. Enteric-coated particles containing TAM (ECP-T) were prepared by spray coating a mixture of ...
full textDevelopment and evaluation of orally disintegrating tablets of Pramipexole using full factorial design
Pramipexole is the mostly prescribed drug in patients with Parkinson disease. The incidence of Parkinson disease is related to aging and mostly developed in elderly people with difficulty in swallowing or dysphagia. In the current study we aimed to develop an orally fast disintegrating tablet (ODT) of pramipexole as a preferable alternative in geriatric patients. Hence, the fast disintegration ...
full textDesign and Development of Ondansetron Orally Disintegrating Tablets and Its Optimization Using Design of Experiment
Ondansetron is the first of a new class of drugs, selective serotonin receptor antagonist (5 hydroxy tryptamine type 3) used as an anti emetic associated with cancer chemotherapy. Its Orally Disintegrating Tablet has been developed for patients who find swallowing difficult by freeze dried technology by RP Scherer Corporation and Scherer DDS. The aim of this study was to design a new orally dis...
full textFormulation and Evaluation of Orally Disintegrating Tablets of Rosuvastatin
Rosuvastatin is a Dyslipidaemic Agents, which acts by inhibition of HMG-CoA reductase enzyme. Used in the treatment of hyperlipidemia. Therefore the present investigation was to design a formulation of orally disintegrating tablets of Rosuvastatin. Orally disintegrating tablets of Rosuvastatin were formulated by Superdisintegrant addition method by direct compression technique. All the fourteen...
full textMy Resources
Journal title
volume 17 issue 4
pages 1150- 1163
publication date 2018-10-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023